Cipher Pharmaceuticals (TSE:CPH) PT Raised to C$19.00 at Stifel Nicolaus

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) had its price objective lifted by equities researchers at Stifel Nicolaus from C$17.00 to C$19.00 in a report issued on Thursday, BayStreet.CA reports. Stifel Nicolaus’ price objective would indicate a potential upside of 17.28% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Stifel Canada upgraded Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, August 12th. Leede Financial cut Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 13th.

Cipher Pharmaceuticals Stock Performance

CPH traded down C$0.28 during trading hours on Thursday, hitting C$16.20. 7,553 shares of the stock were exchanged, compared to its average volume of 46,711. The stock has a 50-day simple moving average of C$16.35 and a 200-day simple moving average of C$11.71. Cipher Pharmaceuticals has a 12 month low of C$4.30 and a 12 month high of C$19.69. The stock has a market cap of C$414.56 million, a price-to-earnings ratio of 13.06 and a beta of 1.20. The company has a debt-to-equity ratio of 0.33, a current ratio of 11.18 and a quick ratio of 2.67.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last announced its quarterly earnings data on Thursday, August 8th. The company reported C$0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of C$0.15 by C$0.01. The firm had revenue of C$7.26 million for the quarter, compared to analysts’ expectations of C$7.52 million. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. Analysts anticipate that Cipher Pharmaceuticals will post 1.6472868 earnings per share for the current year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.